Copyright
©2012 Baishideng.
World J Obstet Gynecol. Oct 10, 2012; 1(3): 35-39
Published online Oct 10, 2012. doi: 10.5317/wjog.v1.i3.35
Published online Oct 10, 2012. doi: 10.5317/wjog.v1.i3.35
Table 1 Patient characteristics and efficacy results of weekly irinotecan + docetaxel and non-pegylated liposomal doxorubicin +/- gemcitabine + G-CSF in the 27 patients with platinum-resistant or platinum-refractory ovarian cancer n (%)
| Weekly Irinotecan + docetaxel | Liposomal doxorubicin +/- gemcitabine + G-CSF | |
| Included/planned | 15/45 | 12/80 |
| Years of study inclusion | 2005-2006 | 2008-2011 |
| Age (yr), median (range) | 56 (33-77) | 65 (46-77) |
| Previous regimens, median (range) | 1.9 (1-4) | 1.6 (1-3) |
| Platinum-refractory disease | 8 (53) | 1 (8) |
| Platinum-resistant disease | 7 (47) | 11 (92) |
| No. of previous chemotherapy regimens | ||
| 1 | 8 (53) | 1 (8) |
| 2 | 3 (13) | 10 (83) |
| 3 | 2 (13) | 1 (8) |
| 4 | 2 (13) | 0 (0) |
| Previous taxanes | 12 (80) | 12 (100) |
| Complete response | 1 (7) | 0 (0) |
| Partial response | 1 (7) | 2 (17) |
| Stable disease | 2 (13) | 2 (17) |
| Progressive disease | 11 (73) | 8 (67) |
| Progression-free survival (mo), median (range) | 2.8 (2.0-3.6) | 2.1 (1.0-9.0) |
| Overall survival from study inclusion (mo), median (range) | 10 (7.8-12.2) | 10 (2.1-44.2) |
- Citation: Petru E, Volgger B, Bogner G, Angleitner-Boubenizek L, Deibl M, Schauer C, Reinthaller A, Wolfram G, Zeimet AG, Marth C. Platinum-resistant ovarian cancer: Prematurely stopped phase II Austrian AGO chemotherapy studies. World J Obstet Gynecol 2012; 1(3): 35-39
- URL: https://www.wjgnet.com/2218-6220/full/v1/i3/35.htm
- DOI: https://dx.doi.org/10.5317/wjog.v1.i3.35